On June 18, according to market news, the clinical-stage ophthalmic biopharmaceutical company Eyenovia announced it will invest $50 million to launch the Hyperliquid (HYPE) treasury reserve strategy.
The content is for reference only, not a solicitation or offer. No investment, tax, or legal advice provided. See Disclaimer for more risks disclosure.
Biotech company Eyenovia launches HYPE treasury reserve strategy, investing $50 million.
On June 18, according to market news, the clinical-stage ophthalmic biopharmaceutical company Eyenovia announced it will invest $50 million to launch the Hyperliquid (HYPE) treasury reserve strategy.